ArticleBMC endocrine disorders2025
Association between serum tumor markers and diabetic nephropathy in type 2 diabetes patients: a cross-sectional survey in Western China.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundDiabetic nephropathy (DN) is a common and serious microvascular complication of type 2 diabetes mellitus (T2DM). However, there is limited clinical research on the use of tumor markers in DN, and the relationship between serum tumor markers and DN in T2DM patients is not well understood. PURPOSE: This study seeks to examine the potential association between serum tumor biomarkers and DN in individuals with T2DM in Western China.
methodsThis cross-sectional study involved 620 T2DM patients, including 253 with DN and 367 without. Differences between the groups were analyzed using Student's t-test, Mann-Whitney U-test, and Pearson's Chi-squared test. Logistic regression assessed the link between serum tumor biomarkers and DN presence, while Spearman's correlation analyzed the relationship between these biomarkers and kidney damage indicators. The diagnostic efficacy of the biomarkers was evaluated through receiver operating characteristic (ROC) curve analysis.
resultsIn patients with T2DM and DN, the serum levels of carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cancer antigen 211 (CA211), cancer antigen 125 (CA125), cancer antigen 199 (CA199), and squamous cell carcinoma antigen (SCC) were significantly elevated compared to those in the non-DN group, while serum levels of pro-gastrin-releasing peptide (ProGRP) were lower than those in the DN group (P < 0.01). After adjusting for potential confounding variables, serum levels of CEA, CA199, and CA125 were found to be independently associated with DN in T2DM patients. The odds ratio (OR) for elevated CEA in relation to DN was 1.41 (95% confidence interval [CI]: 1.17-1.70), for elevated CA125 was 1.02 (95% CI: 1.005-1.036), and for elevated CA199 was 1.021 (95% CI: 1.010-1.032). In this study, the levels of CA125 and CA199 exhibited a negative correlation with estimated glomerular filtration rate (eGFR), with correlation coefficients of -0.16, and -0.089, respectively. Conversely, these biomarkers were positively correlated with albumin-to-creatinine ratio (ACR), with correlation coefficients of 0.56, 0.55, and 0.22, respectively, and with cystatin C levels, with correlation coefficients of 0.17, 0.23, and 0.07, respectively. ROC curve analysis showed that combining CEA, CA125, and CA199 improves the accuracy in distinguishing DN patients, with an AUC of 0.82 (95% CI: 0.79-0.86, P < 0.001).
conclusionsThis study shows that serum tumor markers (CEA, CA125, and CA199) are strongly linked to the presence of DN in type 2 diabetes patients, providing new insights into their role in DN and suggesting potential prevention strategies. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.